Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02231, also known as RP11-766N7.4, is classified as a long intergenic non-coding RNA (lincRNA). LincRNAs are a subclass of nonprotein-coding RNAs that are transcribed from intergenic regions of the genome and typically longer than 200 nucleotides[3][1]. Generally, lincRNAs may act at transcriptional, post-transcriptional, or epigenetic levels and regulate gene expression, though the functions of most individual lincRNAs—including LINC02231—remain uncharacterized[3][1][5]. There is no evidence that LINC02231 is a well-established druggable target, receptor, enzyme, transporter, or has a clearly defined biological or disease role, nor are there any drugs known to interact with it. Its status as a therapeutic target or disease biomarker has not been established in the current literature[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2231 (LINC02231).